Pirfenidone Capsules （400 mg） + Pirfenidone Capsules（600mg） + Pirfenidone Capsules（0mg）
Phase 2/3Recruiting 0 views this week 0 watching⚡ Active
Interest: 45/100
45
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Radiation-induced Lung Injury
Conditions
Radiation-induced Lung Injury, Immune-related Pneumonia
Trial Timeline
Feb 28, 2026 → Oct 30, 2026
NCT ID
NCT07388680About Pirfenidone Capsules （400 mg） + Pirfenidone Capsules（600mg） + Pirfenidone Capsules（0mg）
Pirfenidone Capsules （400 mg） + Pirfenidone Capsules（600mg） + Pirfenidone Capsules（0mg） is a phase 2/3 stage product being developed by Sun Pharmaceutical for Radiation-induced Lung Injury. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07388680. Target conditions include Radiation-induced Lung Injury, Immune-related Pneumonia.
What happened to similar drugs?
0 of 1 similar drugs in Radiation-induced Lung Injury were approved
Approved (0) Terminated (1) Active (0)
Hype Score Breakdown
Clinical
15
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07388680 | Phase 2/3 | Recruiting |
Competing Products
2 competing products in Radiation-induced Lung Injury